IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses

Despite the great impact on long-term survival of some cancer patients, the immune checkpoint blockade (ICB) therapy is limited by its low response rates for most cancers. There is a pressing need for novel combination immunotherapies that overcome the resistance to current ICB therapies. Cytokines...

Full description

Bibliographic Details
Main Authors: Qiuxia Qu, Zhiwei Zhai, Jieni Xu, Song Li, Cheng Chen, Binfeng Lu
Format: Article
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Immunology
Online Access: